Dr. Greg Bertenshaw

Biography

Dr. Greg Bertenshaw, is Vice President, Research & Development. He is responsible for development of the SnapPath® Cancer Diagnostics System and PathMAP® Functional Signaling Profiles. He is also Principal Investigator on all of the National Cancer Institute (NCI) grants and contracts awarded to our Company since the beginning of 2013. This includes the new Phase I NCI contract announced in September 2016, which funds development of initial proof-of-concept data for a potential companion diagnostic to predict individual patient response to immunotherapies for the treatment of non-small cell lung cancer. It also includes the recently awarded Phase I/II NCI Fast Track Grant we announced in June 2016. The Grant announced in June is focused on targeted therapies, and funds development of a different PathMAP® NSCLC companion diagnostic to facilitate selection of optimal therapy for patients with non-small cell lung cancer. It provides for a 2-year $2 million Phase II grant that will begin after we achieve our proposed milestones under a 6-month $300,000 Phase I grant. Dr. Bertenshaw is also Principal Investigator on our ongoing NCI Phase II contract to develop PathMAP® Melanoma as a companion diagnostic to facilitate selection of optimal therapy for patients with melanoma. Before joining BioMarker Strategies, Dr. Bertenshaw was Director of New Technology at Correlogic Systems, Inc., a biomarker discovery company developing in vitro diagnostic tests for ovarian, breast, prostate and colorectal cancers. In particular, Dr. Bertenshaw worked with a multidisciplinary team to develop an immunoassay Luminex-based ovarian cancer diagnostic test (OvaCheck™). Dr. Bertenshaw was involved in all phases of the development from the biomarker discovery phase through submission to the Food and Drug Administration. Dr. Bertenshaw holds a Ph.D. in Biochemistry and Molecular Biology from the Pennsylvania State University College of Medicine, and a B.S. in Biochemistry from University of Manchester, Manchester, United Kingdom

Research Interest

    BioMarker Strategies has developed the proprietary and recently patented SnapPath Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies.